PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29438990-1	2018	Targeting of steroidogenic enzymes (e.g., abiraterone acetate targeting CYP17A1) has been developed as a novel therapeutic strategy against metastatic castration-resistant prostate cancer (CRPC).	Abiraterone Acetate	42-61	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	72-79